文献速递眼底病与葡萄膜炎

微创玻璃体切除术与全视网膜光凝治疗重度非增殖性糖尿病视网膜病变的随机对照试验

Microinvasive pars plana vitrectomy versus panretinal photocoagulation for severe non-proliferative diabetic retinopathy: a randomised controlled trial.
PubMed 文献 · Br J Ophthalmol · 2026-07-17

这项随机对照试验纳入55眼重度非增殖性糖尿病视网膜病变(sNPDR),比较微创玻璃体切除术(PPV)与全视网膜光凝(PRP)12个月内的进展率。结果显示两组进展为增殖性糖尿病视网膜病变(PDR)的比例无显著差异(PPV组0% vs PRP组7.1%,p=0.49),但PPV组周边视野功能保留更好。

要点

  • PPV与PRP在12个月内阻止sNPDR进展为PDR的效果无显著差异。
  • PPV组总视野点评分变化优于PRP组(p=0.02)。
  • PPV组周边60-4视野测试变化同样优于PRP组(p=0.02)。

核心结论

  • 在sNPDR患者中,PPV与PRP在12个月随访期内PDR进展率无显著差异,但PPV组保留了更好的周边视功能。

研究设计与样本

  • 随机对照试验,纳入55例年龄>18岁的sNPDR患者的55眼,1:1随机分为PPV组(n=27)和PRP组(n=28)。
  • PPV组由经验丰富的术者在入组4周内行标准25G PPV,PRP组在入组4周内分三次完成标准PRP。
  • 主要结局为12个月内从sNPDR进展为PDR的眼比例。

主要发现

  • 12个月时,PPV组无患者进展为PDR,PRP组28例中有2例(7.1%)进展,差异无统计学意义(p=0.49)。
  • 总视野点评分平均(SD)变化:PPV组-16.70(415.23)dB,PRP组-314.00(404.59)dB(p=0.02)。
  • 周边60-4测试平均(SD)变化:PPV组-11.39(167.99)dB,PRP组-207.05(308.66)dB(p=0.02)。

关键数值与推荐

  • PPV组27例,平均(SD)年龄61.19(8.89)岁,男性16例(59.3%);PRP组28例,平均(SD)年龄60.50(7.93)岁,男性11例(39.3%)。
  • 12个月PDR进展比例:PPV组0%,PRP组7.1%(2/28),p=0.49。
  • 总视野点评分变化组间比较p=0.02,周边60-4测试变化组间比较p=0.02。

临床怎么用

  • 对于sNPDR患者,PPV与PRP均可作为治疗选择,两者在预防PDR进展方面无显著差异。
  • 若关注周边视功能保护,PPV可能具有一定优势,但需结合患者具体情况个体化决策。

局限性

  • 样本量较小(共55眼),可能影响统计效能。
  • 随访时间仅12个月,长期效果未知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the progression rate of severe non-proliferative diabetic retinopathy (sNPDR) in eyes treated with microinvasive pars plana vitrectomy (PPV) versus panretinal photocoagulation (PRP) over 12 months. METHODS: 55 eyes of 55 diabetic patients aged >18 years with sNPDR were randomised 1:1 to the PPV group (n=27) or the PRP group (n=28). Standard 25G PPV was performed by an experienced surgeon within 4 weeks of enrolment. Standard PRP was performed in three sessions within 4 weeks of enrolment. The primary outcome was the proportion of eyes progressed from sNPDR to proliferative diabetic retinopathy (PDR) over 12 months. RESULTS: A total of 27 participants (mean (SD) age, 61.19 (8.89) years; 16 male (59.3%)) in the PPV group and 28 participants (mean (SD) age, 60.50 (7.93) years; 11 male (39.3%)) in the PRP group were analysed. At 12 months, no patients in the PPV group progressed to PDR, compared with 2 of 28 patients (7.1%) in the PRP group (p=0.49). The mean (SD) change in total visual field point score was -16.70 (415.23) dB in the PPV group and -314.00 (404.59) dB in the PRP group (p=0.02). For the peripheral 60-4 test, the mean (SD) change was -11.39 (167.99) dB in the PPV group versus -207.05 (308.66) dB in the PRP group (p=0.02). CONCLUSIONS: In patients with sNPDR, PPV and PRP showed no significant difference in PDR progression during the 12-month follow-up, whereas the PPV group preserved better peripheral visual function. TRIAL REGISTRATION NUMBER: NCT04103671.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Lin Z, Zheng W, Ding X, et al. Microinvasive pars plana vitrectomy versus panretinal photocoagulation for severe non-proliferative diabetic retinopathy: a randomised controlled trial. Br J Ophthalmol. 2026. PMID: 42469016. doi:10.1136/bjo-2025-328536

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。